Quinnova Pharmaceuticals, Inc. Launches NEOSALUS CREAM

Tue Apr 14, 2009 3:00pm EDT

* Reuters is not responsible for the content in this press release.

NEWTOWN, Pa.--(Business Wire)--
Quinnova Pharmaceuticals, Inc. announced that it has received FDA clearance on
the company`s new product NEOSALUS CREAM, a line extension to the previously
launched NEOSALUS FOAM, the first non-steroidal anti-inflammatory prescription
topical foam product for the treatment of various types of dermatoses including
atopic dermatitis and hand eczema. Both NEOSALUS CREAM and NEOSALUS FOAM are
uniquely formulated with Quinnova`s patented Proderm Technology TM, which
provides skin barrier repair, protection, and moisturization. 

"To treat recalcitrant skin conditions such as atopic dermatitis and hand
eczema, a comprehensive and long term solution is required to address the
underlying issue of a compromised skin barrier while reducing inflammation.
Additionally, to meet patient preferences and increase their compliance, a range
of vehicles containing the same base formulation targeted at treating different
disease states and locations of the body is desirable for both patient
satisfaction and treatment outcome. NEOSALUS CREAM, in addition to NEOSALUS
FOAM, increases the product selection choice of Quinnova`s NEOSALUS brand for
both the patient and the Healthcare Provider," said Dr. Christopher N. Hensby,
Senior Vice President of Quinnova Pharmaceuticals. 

Whether as cream or foam, NEOSALUS helps to restore a dysfunctional skin barrier
by replenishing the lost physiological lipids, thereby decreasing
trans-epidermal water loss (TEWL). Furthermore, NEOSALUS functions as a
protectant to reduce the penetration of irritants from further exacerbating the
itch and scratch cycle. Finally, NEOSALUS has anti-inflammatory ability that
helps to reduce the frequency and severity of flare-ups, thus making it a
steroid sparing and complementary treatment to other concomitant treatments. 

In addition to the therapeutic benefits of NEOSALUS CREAM and NEOSALUS FOAM,
patients will likely appreciate the cosmetic elegance of Proderm Technology TM.
Unlike some creams and lotions which have a tendency to leave the skin feeling
greasy after application, NEOSALUS, a water-lipid based formulation, absorbs
quickly, spreads easily, and is non-greasy. Patients can resume their work and
daily activities immediately after applying NEOSALUS, thus enhancing compliance
and maximizing treatment results. 

Quinnova Pharmaceuticals` sales force calls on dermatologists and podiatrists
across the United States. 

About Quinnova Pharmaceuticals, Inc.

Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of prescription drug products based on
innovative topical drug delivery platforms. For more information, please visit
www.quinnova.com. 





Quinnova Pharmaceuticals, Inc.
Jana Wang, 215-550-2023
jwang@quinnova.com



Copyright Business Wire 2009